Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. demonstrated robust financial performance with a 21% top-line growth in Q3, driven by a 13% increase in volumes and a 5% rise in average selling prices (ASPs), along with record cash collections in October. The company significantly expanded its sales force by approximately 50%, which is expected to further enhance volume growth, particularly following a notable 19% year-over-year increase in kidney surveillance volumes reported in Q2'25. Additionally, CareDx achieved GAAP net income positivity and raised its financial guidance, contributing to a positive market reaction with a 10% rise in the stock price.

Bears say

CareDx Inc. has reported a volume of 50,000 for Q3'25, reflecting a 13% year-over-year growth but falling short of expectations, indicating potential limitations in growth momentum and market dynamics. The company's shares have faced downward pressure, trading at a significant discount to historical averages, with current valuations at 1.4 times the projected $415 million revenue for 2026, compared to the diagnostics sector's higher multiples. Concerns regarding CareDx’s ability to successfully commercialize new diagnostic solutions and instability due to management changes over the past three years further contribute to a negative outlook on its stock performance.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Nov 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.